PMPRB report reviews new drugs that may enter the Canadian market in the near future
| Patented Medicine Prices Review Board Canada | news releases
PMPRB report reviews new drugs that may enter the Canadian market in the near future
News results
Showing 1 - 10 of 80 results
Federal Minister of Health tables the 2024 Annual Report of the Patented Medicine Prices Review Board
| Patented Medicine Prices Review Board Canada | news releases
Sales of patented medicines in Canada were $22.1 billion in 2024, a 10.9% increase over the year before.
Canadian public drug plan spending grew by $3.4 billion over 5 years, driven by use of higher-cost drugs
| Patented Medicine Prices Review Board Canada | news releases
The latest edition of the PMPRB CompassRx report shows that prescription drug expenditure for public drug plans grew by 7.4% in 2022/23 to reach $14.1 billion, compared to $13.2 billion in 2021/22.
PMPRB releases new Guidelines to monitor and review drug prices
| Patented Medicine Prices Review Board Canada | news releases
PMPRB releases new Guidelines to monitor and review drug prices
PMPRB report reviews potential impact of new medicines on the Canadian market
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board published the 9th edition of its annual Meds Entry Watch report today.
Anie Perrault to lead PMPRB as Acting Chairperson
| Patented Medicine Prices Review Board Canada | news releases
Chairperson of the PMPRB, Mr. Thomas Digby has stepped down from his role, effective March 6, 2025.
PMPRB report shows higher-cost medicines driving a 14.1% growth in private plan drug costs in 2023
| Patented Medicine Prices Review Board Canada | news releases
Report explores the drivers of growth in prescription drug costs for private drug plans
Federal Minister of Health tables the 2023 Annual Report of the Patented Medicine Prices Review Board
| Patented Medicine Prices Review Board Canada | news releases
86 new patented medicines were reported to the PMPRB in 2023
PMPRB report reviews new drugs and their potential impact on future drug spending in Canada
| Patented Medicine Prices Review Board Canada | news releases
The latest edition of Meds Pipeline Monitor provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spending in the coming years.
PMPRB report examines availability and pricing of new medicines
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board published the 8th edition of its annual Meds Entry Watch report today.